Jeffrey L. Ives, Director at Cara Therapeutics, Inc. (CARA), sold 3,600 shares at $9.05 ($33K) on 2022-07-15, disclosed to the SEC on 2022-07-19.
Scheduled sale ($33k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CARA | SELL | 2021-06-07 | $33K | — | Filing → |
| CARA | SELL | 2020-11-24 | $39K | — | Filing → |
| CARA | SELL | 2020-06-03 | $16K | — | Filing → |